FIELD: Organic chemistry, medicine, pharmacy. SUBSTANCE: Invention describes novel derivatives of dialkyl ether of the general formula (1) given in the invention description where n and m mean independently each of other whole numbers from 2 to 6; R1,R2,R3R4 mean independently each of other alkyl with carbon atom numbers from one to six; Y1 and Y2 mean independently each of other carboxyl group or group COOR5 where R5 means alkyl with carbon atom numbers from one to six. Indicated compounds are used in pharmaceutical composition eliciting activity with respect to decrease of plasma level of lipoprotein (a), apolipoprotein B, triglycerides, cholesterol complex with lipoproteins of low and very low density and with respect to increase of plasma level of apolipoprotein A-1 or E, cholesterol complex with lipoproteins of high density. Invention describes also method of decrease of plasma level of lipoprotein (a), apolipoprotein B, triglycerides, cholesterol complex with lipoproteins of low or very low density by administration effective dose of compound of the formula (1) as active substance and method of increase of plasma level of cholesterol complex with lipoproteins of high density or apolipoproteins A-1 and E by administration of effective dose of compound of the formula (1) as active substance. Invention describes also method of prophylaxis or treatment of disease of vessels and method of prophylaxis or treatment of insulin-nondependent diabetes mellitus by administration of compound of the general formula (1) as active substance. EFFECT: improved method of treatment and prophylaxis, valuable medicinal properties of compounds. 22 cl, 40 dwg, 12 ex
Title |
Year |
Author |
Number |
SULFAMIC ACID ESTERS, PHARMACEUTICAL COMPOSITION FOR CONTROL OF CHOLESTEROL CONCENTRATION, METHOD OF TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLEMIA, METHOD OF TREATMENT OF PATIENTS WITH ATHEROSCLEROSIS |
1994 |
- Khelen Tsenvej Li
- Dzhozef Armend Pikard
- Drago Robert Sliskovits
- Vendell Virendzhe
|
RU2137756C1 |
DERIVATIVES OF BENZOTHIOPHENE, BENZOFURAN, INDOLETHIAZEPINONE, OXAZEPINONE AND DIAZEPINONE, PHARMACEUTICAL COMPOSITION SHOWING ACTIVITY INHIBITING CELLULAR ADHESION OR HIV-ACTIVITY, METHOD OF INHIBITION OF LEUKOCYTE ADHESION TO ENDOTHELIAL CELLS IN TREATMENT OF DISEASES CAUSED WITH ITS, METHOD OF TREATMENT OF MAMMALS INFECTED WITH HIV-INFECTION |
1995 |
- Dajehn Khehrris Boskelli
- Dejvid Tomehs Konnor
- Dzhejmz Bernard Krejmer
- Pol Charlz Anehngst
|
RU2144033C1 |
METHOD OF TREATMENT OF PATIENTS WITH FEAR STATE OR TREATMENT AND/OR PROPHYLAXIS OF PANIC STATE, PURIFIED PROTEIN ABLE TO BIND GABAPENTIN AND PHARMACEUTICAL COMPOSITION SHOWING SEDATIVE, ANTIPANIC AND ANTICONVULSANT EFFECTS |
1995 |
- Vudraff Dzhoffri Nil
- Dzhi Nikolas S.
- Zing Lakbir
- Braun Dzhejson P.
|
RU2168982C2 |
DERIVATIVES OF 3-ALKYLHYDROXY-, ARYLHYDROXY- OR ARYLALKYLHYDROXY[B]THIOPHENE-2-CARBOXAMIDE, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND PHARMACEUTICAL COMPOSITION SHOWING ACTIVITY INHIBITING ADHESION OF LEUKOCYTES TO VASCULAR ENDOTHELIUM |
1993 |
- Dajen Khehrris Boskelli
- Dehvid Tomas Konnor
- Klifford Din Rajt
|
RU2117665C1 |
METHOD OF PRODUCING SALTS OF 4'-(9-ACRIDINYLAMINO)-METHANSULFON-M-ANISIDINE |
0 |
- Dzhejms R.Fisher
- Charlz P.Kulir
|
SU1192619A3 |
METHODS AND COMPOSITION FOR DECREASING LIPOPROTEIN (a) CONTENT IN PLASMA AND REDUCING FACTORS FOR RISK OF CARDIOVASCULAR DISEASES |
2001 |
|
RU2289406C2 |
METHOD OF PRODUCING NAPHTHYLIDIENE AND QUINOLINE COMPOUNDS |
0 |
|
SU1192624A3 |
SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES, INTERMEDIATE COMPOUNDS AND PHARMCOMPOSITION |
1993 |
- Klifton Dzhon Blehnklej
- Dzhon Kuk Khodges
- Sil'Vester Klachko
|
RU2135473C1 |
METHOD OF PREPARING TRANS-6-[SUBSTITUTED PYRROL-1- YL)ALKYL]PYRAN-2-ON DERIVATIVES AND THEIR DIHYDROXY-CONTAINING ACIDS AND SALTS, HYDROXY-, 1,3-DIOXAN- OR PYRROLE-CONTAINING CARBOXYLIC ACIDS AS INTERMEDIATES FOR PREPARING SAID PYRAN-2-ON DERIVATIVES |
1994 |
- Donal'D Ehjdzhin Batler
- Tung Van Li
- Tomas Norman Nanninga
|
RU2138497C1 |
USE OF 2-PHENYL-3-AROYLBENZOTHIOPHENES FOR SERUM BLOOD CHOLESTEROL DECREASE, PHARMACEUTICAL COMPOSITION |
1995 |
|
RU2150275C1 |